Company: DNLI
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001714899-25-000066
Chunk: 197

Company: Denali Therapeutics Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 9B
Chunk 197
---
Table of Contents

ITEM 9B.    OTHER INFORMATION

Securities Trading Plans of Directors and Executive Officers

Our policy governing transactions in our securities by our directors, officers, and employees permits our officers, directors and employees to enter into trading plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. As disclosed in the table below, during the fourth quarter of 2024, certain of our directors adopted a “Rule 10b5-1 trading arrangement”. This plan provides for the sale of our common stock and is intended to satisfy the affirmative defense in Rule 10b5-1(c).NamePositionDate of Plan AdoptionScheduled End Date of Trading Arrangement(1)Maximum Total Shares of Common Stock to be Sold Under the Plan(2)Carole Ho, M.D.Chief Medical Officer12/11/20243/12/2026373,374 Alexander Schuth, M.D.Chief Operating and Financial Officer12/30/20243/31/2026176,026 __________________________________________________(1)The trading arrangement may expire on an earlier date if and when all transactions under the arrangement are completed.

(2)This amounts represents the maximum total shares that could be sold under the plan, but the amounts may change for executive officers due to the sale of shares to satisfy tax withholding requirements. 

No other officers or directors, as defined in Rule 16a-1(f), adopted and/or terminated of a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408, during the fourth quarter ended December 31, 2024.

Entry into a Material Definitive Agreement

On February 24, 2025, Denali and Sanofi executed a side letter terminating the CNS program portion of their Collaboration Agreement dated October 29, 2018. Under the Collaboration Agreement, certain CNS and peripheral RIPK1 small molecule inhibitors (the "CNS Products" and "Peripheral Products," respectively) were to be developed and commercialized. The side letter terminated provisions of the Collaboration Agreement relating to CNS Products, including Sanofi’s obligations to make milestones or other payments to Denali on future development and commercialization of CNS Products,  and delineated the parties' ongoing rights and obligations. 

Sanofi will continue to develop eclitasertib (SAR443122/DNL758), a Peripheral Product discovered by us,